Previous Close | 88.61 |
Open | 88.34 |
Bid | 87.27 x 400 |
Ask | 87.41 x 500 |
Day's Range | 86.65 - 88.65 |
52 Week Range | 76.02 - 100.38 |
Volume | |
Avg. Volume | 1,331,721 |
Market Cap | 16.479B |
Beta (5Y Monthly) | 0.31 |
PE Ratio (TTM) | 100.39 |
EPS (TTM) | 0.87 |
Earnings Date | Apr 24, 2024 - Apr 29, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 109.48 |
Subscribe to Yahoo Finance Plus to view Fair Value for BMRN
Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Although the Nasdaq Composite is galloping to record highs, amazing deals among growth stocks can still be uncovered.
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that positive early results from an investigator-sponsored Phase 2 study of VOXZOGO® (vosoritide) in children with hypochondroplasia, will be presented at the 2024 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting in Toronto, Canada, March 12-16, 2024. Researchers will also present data from Phase 2 and Phase 3 studies of the medicine in children with achondroplasia, including results that demonstrate V